Christopher Causey's Common Stock Transfer in United Therapeutics Corp

On September 9, 2024, Christopher Causey, a director of United Therapeutics Corp, reported the transfer of 225 shares of common stock from an account jointly held with his son to an account in which he has no beneficial interest. This transfer was done without his knowledge and was discovered recently, leading to an overstatement of his beneficial ownership in subsequent filings. The transaction was reported under Form 4, and the total shares owned following the transaction are 4,640. The filing was signed by John S. Hess, Jr. under Power of Attorney on October 27, 2025.